Group 1 - The company Chongqing Wangbian Electric (603191) expects a net profit attributable to shareholders of 46 million to 54 million yuan for the first half of the year, representing a year-on-year increase of 32.21% to 55.20% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 42 million and 50 million yuan, showing a significant year-on-year growth of 153.79% to 202.13% [1] - The overall performance improvement is attributed to the production of an 80,000-ton high-end magnetic new material project, which has positively impacted the gross profit margin of oriented silicon steel [1] Group 2 - Yunnan Transformer Electric Co., a subsidiary of Wangbian Electric, has seen steady revenue growth in its power distribution and control equipment business, contributing to profit increases [1] - In April 2024, Wangbian Electric successfully acquired 79.97% of Yunnan Transformer Electric, enhancing its supply capacity from 110kV to 500kV [1] Group 3 - Yunnan Transformer Electric's newly developed OSFPSZ18-250000/220 autotransformer has received certification from the KEMA laboratory, a significant achievement for entering high-end markets [2] - The KEMA certification is recognized globally and is essential for market entry in Europe and North America, indicating that the product meets international standards [2] Group 4 - The new 220kV three-phase autotransformer features innovative design elements, including a series coil voltage regulation method and a forced oil circulation cooler integrated into the transformer body [3] - The product underwent rigorous testing, including 39 test items, to meet IEC standards, showcasing its advanced technical performance [4] - The successful certification marks Yunnan Transformer Electric's entry into the global high-end power equipment supplier market, with plans for continuous innovation and integration of international standards [4]

量产积极信号频现，海内外共振有望开启 新行情 ——机器人产业跟踪 核心观点 投资建议与投资标的 人形机器人产业硬件端持续优化降本，智能化领域实现突破性进展，我们认为产业已处 量产前夕。海外扩产步伐积极，国内头部机器人企业上市进程有望加速。建议重点关注 三类产业链优质标的：一是深度绑定海内外头部客户、具备卡位优势的企业；二是布局 前瞻且量产能力有保障的企业；三是自身具备强降本基因的企业，此类标的在行业放量 期有望率先受益。 建议关注：五洲新春(603667，买入)、震裕科技(300953，买入)、赛摩智能(300466，未 评级)、博众精工(688097，未评级)、领益智造(002600，买入)。 风险提示 产品降价风险、场景需求落地不明确导致低于预期、国家政策变化导致行业发展放缓、 海外龙头厂商生产不及预期、行业融资不及预期、模型发展和数据采集慢于预期。 机械设备行业 行业研究 | 动态跟踪 国家/地区 中国 行业 机械设备行业 报告发布日期 2025 年 07 月 11 日 看好（维持） | 龙头继续加码智能物流，看好无人叉车加 | 2025-07-08 | | --- | --- | | 速产业化：——无 ...

7月11日，奥泰生物今日收盘66.9元，上涨1.21%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到16.63倍，总市值53.04亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均52.06倍，行业中值37.22倍，奥泰生物排 名第39位。 股东方面，截至2025年3月31日，奥泰生物股东户数5431户，较上次增加165户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)9奥泰生物16.6317.541.3453.04亿行业平均 52.0649.724.58107.83亿行业中值37.2238.112.4752.18亿1九安医疗10.3010.410.81173.78亿2英科医疗 10.8811.730.97171.88亿3新华医疗14.4413.391.1892.58亿4振德医疗15.4114.530.9855.95亿5奥美医疗 15.5115.201.5956.04亿6山东药玻15.6115.661.79147.65亿7康德莱16.0916.111.3334.68亿8维力医疗 16.6017.261.9537.87 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-044 圣湘生物科技股份有限公司 关于不再设置监事会、修订《公司章程》并办理 工商变更登记及制定、修订部分治理制度的公告 圣湘生物科技股份有限公司（以下简称"公司"）于 2025 年 7 月 10 日召开了第 二届董事会 2025 年第八次临时会议，审议通过了《圣湘生物科技股份有限公司关于 不再设置监事会、修订 <公司章程> 并办理工商变更登记及制定、修订部分治理制度的 议案》。现将有关情况公告如下： 一、关于取消公司监事会的相关情况 为进一步完善公司治理结构，促进公司规范运作，根据《中华人民共和国公司法》 （以下简称"《公司法》"）《上市公司章程指引》《关于新公司法配套制度规则实 施相关过渡期安排》等法律、法规、规范性文件的规定，结合公司的实际情况，公司 拟不再设置监事会，由公司董事会下设的审计委员会行使《公司法》等法律法规规定 的监事会职权，并相应修订《公司章程》及其他相关制度中有关监事、监事会相关的 表述及条款，《圣湘生物科技股份有限公司监事会议事规则》相应废止。 在公司股东会审议通过取消监事会事项前，公司监事会成员仍将严格按照相关法 律法 ...

圣湘生物科技股份有限公司 章程 （2025 年第三次临时股东会审议通过） 二〇二五年七月 第一章总则 第一条 为维护圣湘生物科技股份有限公司（以下简称"公司"）、股东、 职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）和其他有关规定，制订本章程。 第二条 公司系依照《公司法》、《中华人民共和国市场主体登记管理条 例》和其他有关规定成立的股份有限公司。公司由湖南圣湘生物科技有限公司 整体变更发起设立，在长沙市市场监督管理局注册登记，取得营业执照, 统一 社会信用代码为 91430100673566826X。 第三条 公司于 2020 年 7 月 28 日经中国证券监督管理委员会 第六条 公司注册资本为人民币 579,388,006 元。 第七条 公司为永久存续的股份有限公司。 第八条 代表公司执行公司事务的董事为公司法定代表人。董事长为代表 公司执行事务的董事。担任法定代表人的董事或者经理辞任的，视为同时辞去 法定代表人。法定代表人辞任的，公司将在法定代表人辞任之日起三十日内确 定新的法定代表人。 法定代 ...

General Principles - The rules are established to regulate company behavior and ensure shareholders can exercise their rights according to relevant laws and regulations [1][2] - The company must hold shareholder meetings in strict accordance with laws, regulations, and its articles of association [1][2] Types of Shareholder Meetings - Shareholder meetings are categorized into annual and extraordinary meetings, with annual meetings held within six months after the end of the previous fiscal year [1] - Extraordinary meetings must be convened within two months under specific circumstances, such as insufficient board members or significant losses [1] Convening Shareholder Meetings - The board of directors is responsible for convening meetings within the stipulated time frame [3][4] - Independent directors can propose extraordinary meetings, and the board must respond within ten days [3][4] - Shareholders holding more than 10% of shares can request extraordinary meetings, and the board must provide feedback within ten days [4][5] Proposals and Notifications - Proposals must fall within the scope of shareholder meeting authority and comply with legal requirements [6][7] - Shareholders holding at least 1% of shares can submit proposals ten days before the meeting [6][7] - Notifications for annual meetings must be sent 20 days in advance, while extraordinary meetings require 15 days' notice [7] Meeting Procedures - Meetings should be held at the company's registered address or a specified location, and can also utilize electronic communication methods [9][19] - Shareholders must present valid identification to attend meetings, and proxies must have written authorization [10][11] Voting and Decision-Making - Voting can be conducted through various methods, including electronic means, and results must be announced immediately [14][40] - The board must ensure that the meeting proceeds smoothly and address any disruptions [20][21] - Related shareholders must abstain from voting on matters where they have a conflict of interest [12][13] Record Keeping and Compliance - Meeting records must include details such as time, location, attendees, and voting results, and must be preserved for at least ten years [42][43] - Any resolutions passed must comply with legal standards, and disputes regarding the validity of resolutions can be taken to court [46][47] Implementation and Interpretation - The rules take effect upon approval by the shareholder meeting and are subject to interpretation by the board of directors [49][50]

Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that Shengxiang Biotechnology Co., Ltd. is eligible to implement its 2025 restricted stock incentive plan, having complied with relevant laws and regulations [1][2][6]. Group 1: Company Background - Shengxiang Biotechnology was established by the transformation of Hunan Shengxiang Biotechnology Co., Ltd. and was officially registered on August 30, 2019 [4]. - The company received approval from the China Securities Regulatory Commission for its initial public offering, issuing 40 million shares on August 8, 2020, and is listed on the Shanghai Stock Exchange under the stock code 688289 [4]. Group 2: Legal Compliance - The law firm has verified that the company meets all legal requirements to proceed with the incentive plan, including the absence of any conditions that would necessitate termination or suspension of the plan [6][10]. - The firm has confirmed that the company has provided all necessary documentation and that there are no significant omissions or misrepresentations [2][3]. Group 3: Incentive Plan Details - The 2025 restricted stock incentive plan was approved by the company's board on July 10, 2025, and includes provisions for the purpose, management, and distribution of rights among the incentive recipients [7][10]. - The plan specifies that the funding for the incentive will come from the participants' own resources, with the company not providing any financial assistance [12]. Group 4: Impact on Stakeholders - The board's remuneration and assessment committee has indicated that the incentive plan is beneficial for the company's sustainable development and does not harm the interests of the company or its shareholders [12][13]. - The incentive plan's implementation is contingent upon further legal procedures and approval from the shareholders' meeting [9][14].

股票简称：上能电气 股票代码：300827 上能电气股份有限公司 （SINENG ELECTRIC CO., LTD.） （无锡市惠山区和惠路 6 号） 募集说明书 （修订稿） 保荐机构（主承销商） （福州市湖东路 268 号） 公告日期：二零二五年七月 上能电气股份有限公司 2023 年度向特定对象发行股票募集说明书 声 明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露资 料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性、完整 性承担相应的法律责任。 公司负责人、主管会计工作的负责人及会计机构负责人保证募集说明书中财 务会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明对发行人的盈 利能力、投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的 ...

来源：新浪港股-好仓工作室 7月11日，可孚医疗发布公告，宣布董事会已审议通过授权管理层启动境外发行H股并在香港联交所上 市的前期筹备工作。 公司经营：市场竞争激烈，产品结构待优化 从财务数据来看，可孚医疗近年来的业绩表现并不理想。2024年，公司实现营业收入29.83亿元，同比 增长4.53%，增速较以往明显放缓。净利润方面，虽然实现了3.12亿元，同比增长22.6%，但这主要得益 于成本控制和费用优化，并非来自于核心业务的强劲增长。进入2025年，公司业绩更是出现了下滑迹 象，一季度营业收入为7.38亿元，同比减少8.59%；净利润为9143万元，同比减少9.68%。 | 截止日期 | | 2022-12-31 | 2023-12-31 | 2024-12-31 | | --- | --- | --- | --- | --- | | 报告期 | | 年报 | 年报 | 年报 | | 报表类型 | | 合井报表 | 合井报表 | 合井报表 | | ▽ 利润表摘要 | | | | | | 营业总收入 | = | 29.77 | 28.54 | 29.83 | | 同比(%) | 11 0 | 30.82 | ...

证券研究报告 | 公司深度报告 2025 年 07 月 11 日 九号公司（689009.SH） 短交通为基、机器人为翼，成长为智慧生态级玩家 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 10,222 | 14,196 | 20,281 | 26,117 | 32,366 | | 增长率 yoy（%） | 1.0 | 38.9 | 42.9 | 28.8 | 23.9 | | 归母净利润（百万元） | 598 | 1,084 | 1,796 | 2,417 | 3,245 | | 增长率 yoy（%） | 32.5 | 81.3 | 65.7 | 34.6 | 34.3 | | ROE（%） | 10.8 | 17.4 | 22.4 | 23.2 | 23.7 | | EPS 最新摊薄（元） | 0.83 | 1.51 | 2.50 | 3.36 | 4.51 | | P/E（倍） | 69.8 | 38.5 | 23.2 | 17.3 | 12.9 | ...